1. Home
  2. MRUS vs CERT Comparison

MRUS vs CERT Comparison

Compare MRUS & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRUS
  • CERT
  • Stock Information
  • Founded
  • MRUS 2003
  • CERT 2008
  • Country
  • MRUS Netherlands
  • CERT United States
  • Employees
  • MRUS N/A
  • CERT N/A
  • Industry
  • MRUS Biotechnology: Pharmaceutical Preparations
  • CERT Retail: Computer Software & Peripheral Equipment
  • Sector
  • MRUS Health Care
  • CERT Technology
  • Exchange
  • MRUS Nasdaq
  • CERT Nasdaq
  • Market Cap
  • MRUS 2.7B
  • CERT 2.3B
  • IPO Year
  • MRUS 2016
  • CERT 2020
  • Fundamental
  • Price
  • MRUS $40.90
  • CERT $11.98
  • Analyst Decision
  • MRUS Strong Buy
  • CERT Buy
  • Analyst Count
  • MRUS 14
  • CERT 6
  • Target Price
  • MRUS $87.00
  • CERT $15.60
  • AVG Volume (30 Days)
  • MRUS 770.0K
  • CERT 2.8M
  • Earning Date
  • MRUS 05-07-2025
  • CERT 05-05-2025
  • Dividend Yield
  • MRUS N/A
  • CERT N/A
  • EPS Growth
  • MRUS N/A
  • CERT N/A
  • EPS
  • MRUS N/A
  • CERT N/A
  • Revenue
  • MRUS $54,732,000.00
  • CERT $394,498,000.00
  • Revenue This Year
  • MRUS $26.81
  • CERT $11.41
  • Revenue Next Year
  • MRUS $23.85
  • CERT $8.78
  • P/E Ratio
  • MRUS N/A
  • CERT N/A
  • Revenue Growth
  • MRUS 42.77
  • CERT 9.37
  • 52 Week Low
  • MRUS $33.19
  • CERT $8.64
  • 52 Week High
  • MRUS $61.61
  • CERT $17.94
  • Technical
  • Relative Strength Index (RSI)
  • MRUS 45.06
  • CERT 45.14
  • Support Level
  • MRUS $37.92
  • CERT $11.22
  • Resistance Level
  • MRUS $46.36
  • CERT $12.30
  • Average True Range (ATR)
  • MRUS 2.58
  • CERT 0.68
  • MACD
  • MRUS -0.27
  • CERT -0.32
  • Stochastic Oscillator
  • MRUS 35.31
  • CERT 18.37

About MRUS Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Share on Social Networks: